CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB028

Immune Cell Function Assay

Defines reimbursement and coding guidance for immune cell function assays, primarily in the context of monitoring/predicting immune function after solid organ transplantation; applicable to providers submitting claims to BCBSOK.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyImmune Cell Function Assay

Policy CodePolicy CPCPLAB028

Change TypeNo material change

Effective DateFeb 1, 2024

Next Review Date

Key ActionSubmit documentation that supports use of the assay for monitoring or predicting immune function after solid organ transplantation and review member plan documents for coverage and prior authorization requirements.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Post-transplantPrimary reimbursable indication

≥7 indicationsNon-reimbursable uses

3 codesProcedure codes

Feb 1, 2024Policy effective

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursable Indication

Covered when used to monitor and predict immune function after solid organ transplantation.

Primary covered use: Use of an immune cell function assay to monitor and predict immune function after solid organ transplantation may be reimbursable.

Coverage may depend on member plan documents and provider contract.

Not Reimbursable / Excluded Indications

Not reimbursable for the following indications (examples include but are not limited to):

Non-reimbursable uses: a) Management of autologous or allogeneic hematopoietic stem cell transplantation; b) Management of immunodeficiency disorders including human immunodeficiency virus (HIV) and severe combined immunodeficiency disease (SCID); c) Management of or prediction of infection risk in immune-mediated disorders including rheumatoid arthritis (RA), multiple sclerosis, and lupus nephritis; d) Testing for urticaria; e) Diagnosis and management of Lyme disease (for example, iSpot Lyme Test); f) Management of inflammatory bowel diseases; g) Monitoring immune response following surgery.

List is not exhaustive.

The policy permits reimbursement for an immune cell function assay when it is used to monitor and predict immune function after solid organ transplantation. Coverage is limited to this transplant-related context and may depend on member plan documents and provider contracts. Providers should ensure submitted claims and documentation clearly indicate the post–solid organ transplant indication to support payment.

This policy identifies several scenarios where immune cell function assays are not reimbursable. Examples include management of autologous or allogeneic hematopoietic stem cell transplantation; management of immunodeficiency disorders including HIV and SCID; management or prediction of infection risk in immune-mediated disorders such as rheumatoid arthritis, multiple sclerosis, and lupus nephritis; testing for urticaria; diagnosis and management of Lyme disease (for example, iSpot Lyme Test); management of inflammatory bowel diseases; and monitoring immune response following surgery. This list is not exhaustive; claims submitted for these indications are subject to denial.

Provider Actions and Billing Guidance

Prior Authorization

Plan-specific prior authorization

Plan-specific prior authorization requirements may apply to certain products. Providers should review the member's plan documents and benefit coverage to determine whether prior authorization or other product-specific requirements are needed before performing or billing for testing.

Not all laboratory management reimbursement criteria apply to every product; check plan documents for eligible coverage.

Documentation Required

Documentation expectations

Providers are responsible for submission of accurate and complete documentation supporting the medical necessity and coding of services billed. Upon request, providers must submit additional documentation to support the claim, including clinical records, test reports, and rationale for the test ordered.

Submit claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, etc.).
Be prepared to provide additional documentation upon request to support medical necessity and correct coding.

Denial Risk

Denial triggers and coding expectations

Claims may be denied if submitted for non-reimbursable indications or if coding does not conform to industry-standard guidelines and plan/contract terms. Providers should code services according to standard coding guidance and ensure the billed indication is a covered reason per plan documents.

Immune cell function assays may be reimbursable for monitoring/predicting immune function after solid organ transplantation; verify coverage for the specific product and member.
Immune cell function assays are not reimbursable for certain indications including management of hematopoietic stem cell transplantation, immunodeficiency disorders (e.g., HIV, SCID), prediction of infection risk in immune-mediated disorders (e.g., RA, MS, lupus nephritis), testing for urticaria, diagnosis/management of Lyme disease (e.g., iSpot Lyme Test), management of inflammatory bowel diseases, or monitoring immune response following surgery.
Claims are subject to code edit protocols, claim review, provider contract language, medical policies, clinical payment and coding policies, and coding software logic.

Definitions

Immune cell function assay — definition and example modalities

DefinitionImmune cell function assay: a laboratory test measuring cell-mediated immune response (for example, CD4+ T‑cell ATP activity or other cell‑based assays).

Example modality (illustrative)CD4+ T‑cell ATP activity assay (cell‑based measurement of T‑cell function).

Other modalities referencedCell‑based assays assessing allospecific T‑cell responses (e.g., assays used in transplant literature such as ImmuKnow and CD154+ T‑cell assays).

Clinical use contextUsed to monitor and predict immune function in transplant recipients, including assessment of risk for infection or rejection in solid organ transplant populations.

Supporting evidenceMultiple transplant studies and meta-analyses cited in the policy evaluate CD4+ T‑cell function and cell‑based assays for predicting infection and rejection. (See references list in policy).

Background

Immune cell function assays are cell‑based laboratory tests that assess cell‑mediated immune response, for example measuring CD4+ T‑cell activity, and are applied primarily to evaluate risk of infection or rejection in transplant populations. The clinical evidence cited in the policy evaluates assays such as ImmuKnow and other CD4+ T‑cell function tests across solid organ transplant types; however, routine use outside the post‑transplant monitoring context is not supported by this coverage policy.

Transplant-Related Coverage Note

Transplant-related coverage note

Assay use relevant to transplant populations.

Applicable transplant setting: Assays may be reimbursable for monitoring and predicting immune function after solid organ transplantation; specific organ-type criteria are not enumerated in the policy.

Clinical references cited in the policy address kidney, liver, heart, lung and pediatric transplant literature.

Evaluation Requirements

Step Therapy

Review plan documents for product‑specific evaluation and lab management rules

The policy does not list specific pre‑approval evaluation or lab management steps; providers should consult plan documents and member-specific coverage rules for any required pre‑authorization, lab routing, or management protocols.

Because not all lab management reimbursement criteria apply to every product, verify product‑specific rules in the member’s plan documents before ordering.
Supply any requested documentation and follow plan or contract directions for lab provider networks or specimen handling if specified.

Post-Transplant Coverage

Immune cell function assay — post‑transplant monitoring/predictive use

Coverage stanceMay be reimbursable when used to monitor and predict immune function after solid organ transplantation.

Applies toPost‑transplant monitoring for solid organ recipients (kidney, liver, heart, lung and other organs referenced in clinical literature).

Documentation expectationClaims should support that testing is for post‑solid organ transplant monitoring; providers must submit accurate documentation as requested.

Plan variabilityCoverage may depend on the member's plan documents and provider contract; prior authorization requirements are determined by the member's plan documents.

Not a blanket approvalPolicy does not enumerate specific organ‑type criteria or monitoring intervals; clinical judgment and plan rules apply.